98%
921
2 minutes
20
It has previously been shown that highly invasive MDA-MB231 human breast cancer cells express vacuolar proton-translocating ATPase (V-ATPases) at the cell surface, whereas the poorly invasive MCF7 cell line does not. Bafilomycin, a specific V-ATPase inhibitor, reduces the in vitro invasion of MB231 cells but not MCF7 cells. Targeting of V-ATPases to different cellular membranes is controlled by isoforms of subunit a. mRNA levels for a subunit isoforms were measured in MB231 and MCF7 cells using quantitative reverse transcription-PCR. The results show that although all four isoforms are detectable in both cell types, levels of a3 and a4 are much higher in MB231 than in MCF7 cells. Isoform-specific small interfering RNAs (siRNA) were employed to selectively reduce mRNA levels for each isoform in MB231 cells. V-ATPase function was assessed using the fluorescent indicators SNARF-1 and pyranine to monitor the pH of the cytosol and endosomal/lysosomal compartments, respectively. Cytosolic pH was decreased only on knockdown of a3, whereas endosome/lysosome pH was increased on knockdown of a1, a2, and a3. Treatment of cells with siRNA to a4 did not affect either cytosolic or endosome/lysosome pH. Measurement of invasion using an in vitro transwell assay revealed that siRNAs to both a3 and a4 significantly inhibited invasion of MB231 cells. Immunofluorescence staining of MB231 cells for V-ATPase distribution revealed extensive intracellular staining, with plasma membrane staining observed in approximately 18% of cells. Knockdown of a4 had the greatest effect on plasma membrane staining, leading to a 32% reduction. These results suggest that the a4 isoform may be responsible for targeting V-ATPases to the plasma membrane of MB231 cells and that cell surface V-ATPases play a significant role in invasion. However, other V-ATPases affecting the pH of the cytosol and intracellular compartments, particularly those containing a3, are also involved in invasion.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713521 | PMC |
http://dx.doi.org/10.1074/jbc.M901201200 | DOI Listing |
Rep Pract Oncol Radiother
August 2025
Department of Cell Biology, Faculty of Biology, Adam Mickiewicz University, Poznan, Poland.
Background: Triple-negative breast cancer (TNBC) shows a high aggressiveness and chemoresistance. It is important to understand the biology of TNBC, including the influence of immune cells, such as macrophages, on cancer cells (CCs) and their response to chemotherapeutics. The research aimed to determine the effect of cisplatin (CisPt) and paclitaxel (PTX) on the viability, migratory ability and expression of selected genes of TNBC cells co-cultured with macrophages.
View Article and Find Full Text PDFTransl Oncol
August 2025
Department of Breast Center, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing 400030, China. Electronic address:
Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), shows efficient antitumor activity in heavily pretreated metastatic triple-negative breast cancer (TNBC). However, not all patients respond to apatinib, indicating that it is necessary to identify response biomarkers for more precise treatment and investigate the underlying mechanisms of apatinib resistance to develop new treatment strategies for TNBC. In this study, we identified the disheveled binding antagonist of beta-catenin 3 (DACT3) as a biomarker for apatinib sensitivity, as its expression level is significantly higher in apatinib-sensitive patients and positively correlates with longer survival.
View Article and Find Full Text PDFInt J Mol Sci
August 2025
Department of Biochemistry, Donnelly Centre, University of Toronto, Toronto, ON M5S 3E1, Canada.
Disruption of the Hippo pathway leads to activation of the YAP/TAZ transcriptional program which promotes tumor initiation, progression and metastasis in diverse cancers. Aggressive triple-negative breast cancers (TNBC) lack an effective therapy; thus, inactivating YAP and TAZ has emerged as an attractive approach and a new treatment modality. Thus, we performed two complementary high-throughput RNAi-based kinome screens to uncover cancer-associated activators of YAP/TAZ in two TNBC cell lines, MDA-MB231 and MDA-MB468.
View Article and Find Full Text PDFInt J Nanomedicine
August 2025
Medical Research Core Facility and Platforms, King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia.
Background And Aim: Nanotechnology offers a promising approach to address breast cancer and bacterial resistance, two critical global health challenges. This study synthesized silver nanoparticles (AgNPs) using extracts from ( (. and ( to evaluate their potential as novel therapeutic agents.
View Article and Find Full Text PDFBiochim Biophys Acta Mol Basis Dis
August 2025
Life Sciences Institute, Guangxi Medical University, 530021 Nanning, China; Guangxi Medical University Cancer Hospital, Guangxi Medical University, 530021 Nanning, China. Electronic address:
Triple-negative breast cancer (TNBC) is associated with poor prognosis and high rates of metastasis and recurrence owing to lack of targeted therapies. Therefore, identifying effective targets for TNBC therapy remains an important clinical challenge. In this study, we examined the potential anticancer mechanisms and targets of the anthraquinone modifier KA-4c.
View Article and Find Full Text PDF